Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Liver and Pancreas Tumors
How do you treat de novo metastatic hepatocellular carcinoma in a non-cirrhotic patient with a prior orthotopic liver transplant for hepatitis B now on chronic immunosuppression?
Related Questions
How long should surgery be delayed in a patient with localized, resectable pancreatic cancer who developed acute pancreatitis following EUS guided biopsy?
Would you still offer adjuvant chemo at 24 weeks post Whipple for a pT1c pN2 cM0 neg margins ampullary adenocarcinoma?
How would active Crohn's on Adalimumab affect the adjuvant management of a T2aN0M0 gallbladder cancer?
Would you ever consider using durvalumab/tremelimumab in second line after progression on Atezolizumab and Bevacizumab in advanced HCC?
What are your first line treatment choices for metastatic combined HCC/Cholangiocarcinoma?
In patients with perihilar cholangiocarcinoma eligible for liver transplant, what is the protocol for neoadjuvant chemo-RT, particularly when brachytherapy is not available?
How would you treat an MSI-H metastatic cholangiocarcinoma found on liquid biopsy?
How do you sequence hypofractionated radiation and systemic therapy for patients with unresectable cholangiocarcinoma?
How would you manage a solitary unresectable liver metastasis?
In patients with resected PDAC treated with adjuvant FOLFIRINOX who recur from 1-3 years post completion of adjuvant therapy, do you consider retreatment with FOLFIRINOX or gemcitabine/nab-paclitaxel in the absence of a clinical trial?
